logo

For the Inventor, By the Inventor

New Haven, CT, United States of America

Curagen Corporation


USPTO Granted Patents = 84

% Expired Patents = 32.1



Forward Citations = 2,352

Loading Chart...
Loading Chart...

122 inventors (with patents filed for the assignee):

goldMedal Jonathan Marc Rothberg (23 out of 403 patents)

silverMedal Richard August Shimkets (21 out of 24 patents)

bronzeMedal John W Simpson (16 out of 30 patents)

4.  Michael W Deem (12 out of 13 patents)

5.  Krishnan Nandabalan (11 out of 18 patents)

6.  Meijia Yang (11 out of 11 patents)

7.  Gregory T Went (10 out of 10 patents)

8.  Luca Rastelli (8 out of 16 patents)

9.  Catherine Burgess (7 out of 8 patents)

10.  Michael Jeffers (6 out of 8 patents)

11.  Ferenc L Boldog (6 out of 10 patents)

12.  Sudhirdas K Prayaga (6 out of 6 patents)

13.  Muralidhara Padigaru (6 out of 7 patents)

14.  Kimberly Spytek (6 out of 8 patents)

15.  John R MacDougall (6 out of 8 patents)


Core Competencies:
Antibodies
Polypeptides
Nucleic Acids
Cytokines
FGF Proteins
Gene Expression
Biological Macromolecules
Inflammatory Bowel Disease
Cancer Diagnostics
Stroke
Therapeutic Proteins
Cardiac Hypertrophy

84 patents:

1. 8067544 - Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof (2011-11-29),
2. 7566536 - WNT-regulated cytokine-like polypeptide and nucleic acids encoding same (2009-07-28),
3. 7291483 - FGF-CX polynucleotide sequences and methods of producing same (2007-11-06),
4. 7276593 - Proteins and nucleic acids encoding same (2007-10-02),
5. 7259144 - Methods for diagnosing and treatment of hyperphosphatemic conditions using FGF20 polypeptides (2007-08-21),
6. 7253266 - Polypeptides of FGF-CX (2007-08-07),
7. 7189693 - Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides (2007-03-13),
8. 7122345 - Nucleic acid encoding a NOVX13 polypeptide (2006-10-17),
9. 7112668 - Polypeptides and nucleic acids encoded thereby (2006-09-26),
10. 7109000 - Proteins and nucleic acids encoding same (2006-09-19),
11. 7108972 - Proteins, polynucleotides encoding them and methods of using the same (2006-09-19),
12. 7060444 - Zone 3 necrosis associated markers and method of use thereof (2006-06-13),
13. 7056885 - Fibroblast growth factor and nucleic acids encoding same (2006-06-06),
14. 7045509 - Proteins and nucleic acids encoding same (2006-05-16),
15. 7033790 - Proteins and nucleic acids encoding same (2006-04-25),
Company Overview
Curagen Corporation, based in New Haven, CT, is a leader in biomedical research, focusing on the development of innovative therapies and diagnostics. The company specializes in advanced technologies related to antibodies, polypeptides, nucleic acids, and cytokines, with a particular emphasis on addressing complex conditions such as inflammatory bowel disease. By leveraging its expertise in gene expression and biological macromolecules, Curagen aims to contribute significantly to the advancement of healthcare solutions and improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Curagen Corporation USPTO Patent Assignee Logo
84 Patents

#5 in New Haven, CT

#122 in Connecticut

#4,431 in US

#9,061 in the World

New Haven, CT (US)
New Haven, CT, United States of America

Curagen Corporation

Forward Citations = 2,352

122 inventors:

goldMedal Jonathan Marc Rothberg (23 out of 403 patents)

silverMedal Richard August Shimkets (21 out of 24 patents)

bronzeMedal John W Simpson (16 out of 30 patents)

4.  Michael W Deem (12 out of 13 patents)

5.  Krishnan Nandabalan (11 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Curagen Corporation. Retrieved from https://idiyas.com/company/curagen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…